Animals that hibernate are incredibly resilient. They can spend months without food or water, muscles refusing to atrophy, body temperature dropping to near freezing as their metabolism and brain activity slow to a crawl. When they emerge from hibernation, they recover from dangerous health changes similar to those seen in type 2 diabetes, Alzheimer’s disease, and stroke.
To diagnose either type 2 diabetes or pre-diabetes, clinicians typically rely on a lab value known as HbA1c. This test captures a person’s average blood glucose levels over the previous few months. But HbA1c cannot predict who is at highest risk of progressing from healthy to prediabetic, or from prediabetic to full-blown diabetes.
SetPoint Medical announced today that the FDA approved its SetPoint neuroimmune modulation system for treating rheumatoid arthritis (RA).
AUSTIN, Texas, July 30, 2025 /PRNewswire/ — Alafair Biosciences, a medical device company redefining soft-tissue protection in orthopedic surgery, announced today that it has received two 510(k) clearances from the FDA for VersaCoat™ Tendon Protector and VersaCoat™ Nerve Protector, marketed as a single product, VersaCoat™ Flowable Hydrogel.
Bioventus (Nasdaq:BVS) announced today that it received FDA 510(k) clearance for both its TalisMann and StimTrial offerings.
Researchers from RMIT University have developed a wearable wound monitoring device with integrated sensors that could reduce infection risks by minimizing the need for frequent physical contact. Their study, “Multiplexed cutaneous wound monitor for point-of-care applications,” was published in Advanced NanoBiomed Research.
Miniaturization and weight reduction of medical wearable devices for continuous health monitoring such as heart rate, blood oxygen saturation, and sweat component analysis remain major challenges.
Modern medicine is largely reactive—treating illness only after symptoms emerge. But a new study from the Research Institute of the McGill University Health Center (The Institute) and McGill University points to a more proactive future: one where silent signs of infection are detected before we even feel sick.
For nearly three decades, Mayo Clinic researcher Christopher Evans, Ph.D., has pushed to expand gene therapy beyond its original scope of fixing rare, single-gene defects. That has meant systematically advancing the field through laboratory experiments, pre-clinical studies and clinical trials.
FRANKLIN LAKES, N.J., July 30, 2025 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the BD Veritor™ System for SARS-CoV-2, a digital test designed to detect COVID-19 antigens in symptomatic individuals in about 15 minutes at doctors’ offices, urgent care centers, retail clinics and other convenient points of care.